A precision medicine–based, ‘fast-fail’ approach for psychiatry
- 17 April 2020
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 26 (5), 653-654
- https://doi.org/10.1038/s41591-020-0854-z
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedoniaNature Medicine, 2020
- Depression Is the Leading Cause of Disability Around the WorldJama-Journal Of The American Medical Association, 2017
- Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical TrialsDepression and Anxiety, 2016
- Mental Disorders Top The List Of The Most Costly Conditions In The United States: $201 BillionHealth Affairs, 2016
- Assessing anhedonia in depression: Potentials and pitfallsNeuroscience & Biobehavioral Reviews, 2016
- Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptomsPsychological Medicine, 2011
- Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental DisordersAmerican Journal of Psychiatry, 2010
- Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D ReportAmerican Journal of Psychiatry, 2006
- Lack of Ventral Striatal Response to Positive Stimuli in Depressed Versus Normal SubjectsAmerican Journal of Psychiatry, 2006
- The Neural Correlates of Anhedonia in Major Depressive DisorderBiological Psychiatry, 2005